Celsion Presents Preliminary Breast Cancer Treatment Results at 56th Annual Cancer Symposium, Society of Surgical Oncology.

Business Editors/Health/Medical Writers

COLUMBIA, Md.--(BUSINESS WIRE)--March 10, 2003

96% of Lumpectomy Patients Treated with Thermotherapy in Study Require

No Further Surgery

CELSION CORPORATION (AMEX:CLN) has announced that Dr. Hernan I. Vargas, co- principal investigator for Celsion's Pivotal Breast Cancer Clinical Trials and Chief of Surgical Oncology at Harbor UCLA Medical Center, Torrance, CA, presented preliminary results for Celsion's investigational therapy for breast cancer treatment at the 56th Annual Cancer Symposium, sponsored by the Society of Surgical Oncology, in Los Angeles, CA, on March 8, 2003.

In the study, conducted at Harbor UCLA Medical Center, Columbia Hospital in West Palm Beach, FL, the University of Oklahoma, Oklahoma City and Halle Martin Luther Breast Center in Halle, Germany, 24 out of 25 early breast cancer cases (96%) treated with Adaptive Phased Array (APA) microwave therapy prior to lumpectomy achieved "clean" margins and required no further surgery to remove cancer cells not excised in the first surgery.

Nationally published surveys indicate that second incisions are required, following lumpectomies, in between 25-to 55% of all cases.

Dr. Vargas characterized these preliminary results as "encouraging" and added, "I expect the presentation to generate genuine enthusiasm in the medical community for Celsion's very promising minimally invasive approach." Dr Vargas went on to comment, "In 24 out of the 25 early stage breast cancer cases treated, post treatment pathology indicated that the margins of the treated tumor were clear of all viable cancer cells. As a result, the surgeons were not required to make further incisions to remove cancer cells remaining from the original surgery. While the preliminary results are not conclusive, we believe that, when the fully randomized study is completed and analyzed, the data, will demonstrate the effectiveness of this investigational treatment. If proven effective, this treatment would mark a significant step forward in the treatment of breast cancer and breast conservation. Preliminary results from this dose escalation study have been quite positive," concluded Dr. Vargas.

Typically, when a woman has breast cancer, she undergoes a lumpectomy to excise the cancer tumor. The goal is to completely remove the tumor and any viable cancer cells in the vicinity (margins) of the tumor, leaving the breast cancer free. Success of the surgery is verified by a post-operative examination of the excised tissue surrounding the tumor.

If the examination determines that viable cancer cells remain, the surgeon must make a second incision (re-excise) the breast to remove the remaining cancerous cells.

Celsion's unique procedure, which is performed in a outpatient setting prior to lumpectomy, uses Adaptive Phased Array (APA) technology to focus microwave heat in a highly targeted manner to kill cancer cells.

Originally developed at the Massachusetts Institute of Technology (MIT) for use in the "Star Wars" missile defense system, this technology heats and destroys cancer cells while leaving healthy tissue intact.

Celsion is also conducting, in parallel, a second pivotal study using a combination of its APA technology in conjunction with chemotherapy to downstage large, advanced stage breast tumors, currently indicated for radical mastectomy, with the goal of shrinking the breast cancer lesion so that a breast conserving partial mastectomy or lumpectomy can be performed instead.

In addition to Harbor-UCLA in CA the Pivotal Phase II trials are now in progress at Columbia Hospital in West Palm Beach, FL; the University of Oklahoma, Oklahoma City, OK; Comprehensive Breast Center of Coral Springs, Coral Springs, FL; Mroz-Baier Breast Care Clinic, Memphis, TN; Breast Care Specialists, P.C., Norfolk, VA and Pearl Place Breast Center, Tacoma, WA.

Anyone interested in participating in the trials should call Celsion at 800.262.0394 and ask for Celsion's Medical Director, Dr. William Gannon.

About Celsion: Celsion Corporation, based in Columbia, Maryland, is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused-heat technology delivered by patented microwave technology.

In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX) in which Boston Scientific will initially distribute Celsion's BPH product worldwide. Boston Scientific currently owns approximately 9% of Celsion's outstanding stock.

Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, the Center for Breast Surgery at Columbia Hospital in Florida, Montefiore Medical Center, Memorial Sloan-Kettering Cancer Center in New York, Roswell Park Cancer Institute in Buffalo, New York, and Duke University.

For more information on Celsion, visit our website: www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.